In8Bio Inc (INAB)

$0.25 -0.02 (-7.43%)
Market Cap 19.85M
Revenue (ttm) 0.00
Net Income (ttm) -30.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 729,900
Avg Vol 721,420
Day's Range N/A - N/A
Shares Out 72.48M
Stochastic %K 21%
Beta 0.04
Analysts Strong Sell
Price Target $3.83

Latest News on INAB

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Dec 10, 2024, 7:00 AM EST - 7 weeks ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 12, 2024, 4:26 PM EST - 2 months ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Sep 4, 2024, 4:01 PM EDT - 5 months ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 6:05 AM EDT - 5 months ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Aug 12, 2024, 8:05 AM EDT - 6 months ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 7 months ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 13, 2024, 4:01 PM EDT - 8 months ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

Jun 3, 2024, 6:05 AM EDT - 8 months ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 24, 2024, 8:00 AM EDT - 8 months ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 9 months ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 14, 2024, 10:00 AM EDT - 9 months ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 13, 2024, 8:00 AM EDT - 9 months ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 9, 2024, 4:00 PM EDT - 9 months ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 30, 2024, 6:05 AM EDT - 9 months ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 10 months ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 16, 2024, 4:05 PM EDT - 10 months ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Apr 9, 2024, 4:30 PM EDT - 10 months ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 14, 2024, 4:00 PM EDT - 11 months ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 11 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 1 year ago

IN8bio to Present at Upcoming Investor Conferences

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Feb 14, 2024, 8:00 AM EST - 1 year ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Jan 4, 2024, 8:00 AM EST - 1 year ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 4:05 PM EST - 1 year ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 11, 2023, 9:00 AM EST - 1 year ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 7, 2023, 8:00 AM EST - 1 year ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Dec 5, 2023, 8:00 AM EST - 1 year ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Nov 20, 2023, 7:00 AM EST - 1 year ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Nov 10, 2023, 7:00 AM EST - 1 year ago

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 4:00 PM EST - 1 year ago

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 6, 2023, 8:00 AM EST - 1 year ago

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Nov 3, 2023, 12:00 PM EDT - 1 year ago

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:17 AM EDT - 1 year ago

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

Nov 1, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

Oct 12, 2023, 8:00 AM EDT - 1 year ago

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

Sep 29, 2023, 8:00 AM EDT - 1 year ago

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

Sep 26, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 20, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

Sep 19, 2023, 8:03 AM EDT - 1 year ago

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 15, 2023, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 4:15 PM EDT - 1 year ago

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility

Aug 8, 2023, 8:00 AM EDT - 1 year ago

IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 1 year ago

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

May 17, 2023, 8:00 AM EDT - 1 year ago

IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 8:00 AM EDT - 1 year ago

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting

May 2, 2023, 5:08 PM EDT - 1 year ago

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

May 1, 2023, 8:00 AM EDT - 1 year ago

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting

Apr 26, 2023, 10:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting

IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma

Apr 25, 2023, 8:00 AM EDT - 1 year ago

IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma

IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023

Apr 24, 2023, 8:00 AM EDT - 1 year ago

IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023